Market Overview

HeartSciences Named Among '50 Smartest Companies of the Year 2018' by The Silicon Review Magazine


Silicon Review, a leading Business and Technology magazine has named HeartSciences,
as one of the 50
Smartest Companies of the Year 2018

This press release features multimedia. View the full release here:

MyoVista Wavelet ECG Cardiac Testing Device (Photo: Business Wire)

MyoVista Wavelet ECG Cardiac Testing Device (Photo: Business Wire)

"The Silicon Review 50 Smartest Companies of the Year 2018 program
identifies companies that mastered the discipline of smartness and stood
high among the crowd,"
said Sreshtha Banerjee, Editor-in-Chief of
The Silicon Review Magazine.

"We are honored to be recognized by The Silicon Review Magazine as
the one of the 50 Smartest Companies of 2018,
" said Mark Hilz, CEO
at HeartSciences. "HeartSciences use of patented signal processing
methods combined with artificial intelligence is designed to bridge
today's "diagnostic gap" in cardiac care by providing low-cost effective
solutions that help to identify cardiac dysfunction in the diastolic

About HeartSciences

HeartSciences is advancing the field of electrocardiography through the
application of Wavelet Signal Processing and Artificial Intelligence to
develop next generation ECG technology. Wavelet signal processing is
currently used in many different industries as an important tool to
provide insights and new valuable data related to spectral analysis of a
signal. HeartSciences' MyoVista
Cardiac Testing Device is a 12-lead resting
electrocardiograph utilizing continuous wavelet transform (CWT) based
signal processing. Patented informatics focus on energy related
information rather than conventional voltage-based information.
HeartSciences mission is to enable accurate, affordable screening for
the early detection of heart disease.

In addition to the proprietary informatics, the MyoVista wavECG
device also features the capabilities of a full featured 12-lead resting
ECG including analysis using the Glasgow Algorithm, one of the world's
most respected interpretive algorithms. The device has a 15.6-inch
high-resolution touchscreen display and incorporates many features
commonly associated with a tablet device requiring minimal user training
as well as easy and intuitive use. The MyoVista wavECG device is
not currently approved for sale or distribution in the United States and
is not currently FDA cleared.

is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit:


The following link leads to a multimedia support platform designed to
provide rapid download of media elements needed to develop your story
about HeartSciences and MyoVista Technology.

View Comments and Join the Discussion!